{"id":"W4214685750","doi":"10.1136/jitc-2021-003776","title":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; American Society of Clinical Oncology; Novartis","keywords":"Medicine; Adverse effect; Dosing; Internal medicine; Oncology; Cancer; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009571904,0.001013658,0.001559323,0.0002941837,0.0002695521,0.0005491056,0.0004365322,0.0004970749,0.00208862],"category_scores_gemma":[0.0004619437,0.0004164036,0.0007233756,0.0002435636,0.0005746095,0.0004173156,0.0002569856,0.001565295,0.0004428496],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007178919,"about_ca_system_score_gemma":0.001098195,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006390285,"about_ca_topic_score_gemma":0.001465065,"domain_scores_codex":[0.9997525,0.0000999921,0.00001411213,0.00005626267,0.00002459186,0.00005267691],"domain_scores_gemma":[0.9996992,0.00004029127,0.00004963758,0.00002282265,0.00001415266,0.0001737646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5396656,0.0902372,0.01927827,0.0007275066,0.0009998215,0.0004087138,0.0004474836,0.005281021,0.1379805,0.0005094574,0.00388386,0.2005805],"study_design_scores_gemma":[0.3622696,0.6000337,0.0208798,0.0000348921,0.0004618463,0.0003883765,0.00008270575,0.002112482,0.009741401,0.0002668478,0.003704227,0.0000240935],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949657,0.001281537,0.0005102415,0.0001804735,0.00005607693,0.00150005,0.0003476118,0.00005391713,0.001104231],"genre_scores_gemma":[0.9947956,0.0008712543,0.001193973,0.0002879349,0.00006730622,0.001068825,0.0007048618,0.000009665489,0.001000565],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00208862,"threshold_uncertainty_score":0.006987095,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01189213994870178,"score_gpt":0.3023932276310027,"score_spread":0.290501087682301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}